IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 5, April 2025
Impact Factor: 7.67

Review on Alopecia Areata

Patil Abhay[1], Omkar Naik[2], Omkar Patil[3], Prajakta Indalkar[4], Hake Balaji[5], Zodage A. B[6].
Students, Shivlingeshwar College of Pharmacy Almala, Latur, Maharashtra[1,2,3,4,5]
Assistant Professor, Shivlingeshwar College of Pharmacy Almala, Latur, Maharashtra[6]

Abstract: *Alopecia areata (AA) is an autoimmune disorder characterized by non-scarring hair loss due to immune-mediated attack on hair follicles. The disease affects individuals of all ages and has a significant psychological impact. This review aims to provide a comprehensive analysis of AA, including its historical background, pathophysiology, and treatment options. The pathogenesis of AA involves the collapse of hair follicle immune privilege, activation of autoreactive CD8+ T cells, and increased expression of pro-inflammatory cytokines such as interferon-gamma (IFN-γ) and interleukin-15 (IL-15). Genetic predisposition plays a crucial role, with susceptibility loci identified in immune-related genes, including PTPN22 and IL2RA. Environmental factors such as stress and infections are also implicated in triggering the disease.Current treatment strategies include synthetic and herbal approaches. Corticosteroids and immunomodulators remain the mainstay of therapy, while Janus kinase (JAK) inhibitors, such as tofacitinib and baricitinib, have emerged as promising targeted therapies. Herbal treatments, including ginseng, rosemary, and curcumin, offer alternative options with anti-inflammatory and antioxidant properties. Despite advancements in treatment, AA remains a challenging condition with variable response to therapy and a high relapse rate. Further research is needed to elucidate the disease mechanisms and develop more effective, personalized treatment strategies. This review highlights recent developments in AA research and underscores the need for continued exploration of novel therapeutic approaches to improve patient outcomes..*

Keywords: Alopecia Areata, autoimmune disorder, hair follicle immune privilege, Janus kinase inhibitor, corticosteroid, herbal therapy, immunomodulation

I. INTRODUCTION

Alopecia areata (AA) is a common autoimmune disorder characterized by sudden, non-scarring hair loss, primarily affecting the scalp but sometimes extending to other body areas. The disease is unpredictable, presenting as isolated hair loss patches or progressing to complete baldness of the scalp (alopecia totalis) or the entire body (alopecia universalis). While not life-threatening, AA significantly affects patients' psychological well-being and quality of life (Gilhar et al., 2019). The etiology of AA is multifactorial, involving genetic predisposition, environmental triggers, and immune system dysregulation. Recent advancements in immunology have identified key cytokines, such as interferon-gamma (IFN-γ) and interleukin-15 (IL-15), which play a crucial role in hair follicle autoimmunity (Strazzulla et al., 2018). The earliest descriptions of alopecia areata date back to ancient civilizations. The Greek physician Hippocrates (460-370 BCE) mentioned cases of patchy hair loss resembling modern-day alopecia areata. Similarly, Galen (129-216 CE) documented hair loss conditions and attributed them to imbalances in bodily humors, a prevailing medical theory at the time (Messenger &Christiano, 2014). During the Middle Ages and the Renaissance, AA was often misunderstood and attributed to supernatural causes or infections.

In the 19th and early 20th centuries, medical understanding of AA improved, and dermatologists began differentiating it from other forms of hair loss. Henry Radcliffe Crocker, a prominent British dermatologist, classified alopecia areata as a distinct disease in 1888, moving away from earlier beliefs that associated it with fungal infections (Crocker, 1888). By the mid-20th century, researchers started recognizing the autoimmune nature of AA, leading to the first histopathological studies revealing lymphocytic infiltration around affected hair follicles (McDonagh& Messenger, 1996). The late 20th and early 21st centuries saw significant advancements in understanding AA's pathogenesis, particularly in genetics and immunology. Genome-wide association studies (GWAS) identified multiple susceptibility

DOI: 10.48175/IJARSCT-25275

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 5, April 2025
Impact Factor: 7.67

loci, including genes involved in immune regulation, such as PTPN22, IL2RA, and CTLA4, highlighting the genetic predisposition of the disease (Petukhova et al., 2010). Further, the discovery of Janus kinase (JAK) inhibitors as a promising treatment has revolutionized AA therapy, with drugs like baricitinib receiving FDA approval in 2022 (King et al., 2022).

Today, alopecia areata is recognized as a T-cell-mediated autoimmune disorder, with hair follicle immune privilege collapse playing a central role. The psychological and social impact of AA is profound, with many patients experiencing depression, anxiety, and diminished self-esteem (Gupta et al., 2019). Treatment strategies range from corticosteroids and immunotherapy to emerging targeted therapies like JAK inhibitors, which have shown promising results in clinical trials (Jabbari et al., 2016). Despite these advancements, many aspects of AA remain unknown, including the precise environmental triggers and long-term efficacy of new treatments. Continued research is essential to improve therapeutic outcomes and provide personalized treatment strategies. As the field of dermatology advances, a more comprehensive understanding of AA's pathogenesis will pave the way for better disease management and improved patient care.

Objective of the Study:-

The objective of this study is to provide a comprehensive review of alopecia areata, focusing on its pathogenesis, clinical presentation, historical context, and emerging treatment options. This study aims to summarize current research findings on the genetic and immunological mechanisms underlying AA, explore the psychological and social impact of the disease, and evaluate advancements in therapeutic approaches, particularly the role of Janus kinase (JAK) inhibitors. By synthesizing recent literature, this review seeks to enhance understanding of AA and contribute to the development of more effective, personalized treatment strategies for affected individuals.

Pathophysiology of Alopecia Areata

Alopecia areata is a complex autoimmune disorder primarily affecting the hair follicle. The pathophysiology of AA involves a breakdown of immune privilege, an aberrant immune response against hair follicle structures, genetic predisposition, and environmental triggers. Research suggests that a combination of genetic susceptibility and immune dysregulation contributes to the development and progression of the disease (Gilhar et al., 2019).

Hair follicles maintain immune privilege by suppressing the expression of major histocompatibility complex (MHC) class I and II molecules, thereby avoiding immune surveillance. In AA, this immune privilege collapses, leading to the exposure of follicular antigens to autoreactive T cells (Paus et al., 2018). The collapse is mediated by increased expression of inflammatory cytokines such as interferon-gamma (IFN-γ) and interleukin-15 (IL-15), which enhance antigen presentation and promote the activation of cytotoxic CD8+ T cells (Petukhova et al., 2010). These T cells infiltrate the hair follicle and release pro-inflammatory cytokines, leading to follicular miniaturization and hair loss (Strazzulla et al., 2018).

Synthetic and Herbal Treatment for Alopecia Areata

The treatment of alopecia areata includes both synthetic and herbal approaches aimed at suppressing the immune response and stimulating hair regrowth. Synthetic treatments primarily include corticosteroids, immunomodulators, and targeted therapies such as Janus kinase (JAK) inhibitors. Corticosteroids, administered topically, intralesionally, or systemically, are the first-line treatment for AA due to their immunosuppressive effects (Rashighi& Harris, 2017). Minoxidil, although primarily used for androgenetic alopecia, is also prescribed for AA as it promotes hair follicle survival and prolongs the anagen phase (Messenger &Christiano, 2014). JAK inhibitors, such as tofacitinib and baricitinib, have shown significant efficacy in clinical trials by targeting inflammatory pathways involved in AA pathogenesis (King et al., 2022).

Herbal treatments have also gained attention for their potential in managing AA. Traditional medicinal plants such as ginseng (Panax ginseng), rosemary (Rosmarinusofficinalis), and onion (Allium cepa) have been reported to promote hair growth due to their anti-inflammatory and antioxidant properties (Rossi et al., 2018). Essential oils, including peppermint and lavender oil, have demonstrated efficacy in enhancing hair follicle activity and reducing inflammation

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 5, Issue 5, April 2025 Impact Factor: 7.67

(Hay et al., 2016). Moreover, herbal formulations containing curcumin and green tea polyphenols have been explored for their immunomodulatory effects in AA treatment (Hosseini et al., 2019).

While synthetic treatments offer rapid and targeted effects, herbal remedies provide alternative approaches with fewer side effects. Future research is needed to validate the efficacy and safety of these treatments through controlled clinical trials.

II. CONCLUSION

Alopecia areata is a complex autoimmune disorder with a multifactorial etiology involving genetic susceptibility, immune dysregulation, and environmental triggers. While the understanding of its pathophysiology has significantly advanced, particularly in the areas of immune privilege collapse and T-cell-mediated follicular attack, many aspects of the disease remain unclear. The psychological and social implications of AA further emphasize the need for effective, long-term treatment strategies.

Current treatment modalities, including corticosteroids, immunomodulators, and JAK inhibitors, have shown varying degrees of success, but their efficacy is often limited by side effects and relapse rates. Herbal and alternative therapies, such as ginseng, rosemary, and curcumin, provide additional options with potential therapeutic benefits, though further clinical validation is required. The advent of targeted therapies, particularly JAK inhibitors, has revolutionized AA treatment, yet challenges remain in ensuring long-term remission and minimizing adverse effects.

Despite these advancements, AA continues to pose significant therapeutic challenges, necessitating further research into its immunological mechanisms and novel treatment approaches. A multidisciplinary approach that combines immunological insights with personalized medicine is essential to improving disease outcomes. Future studies should focus on refining existing treatments, exploring novel therapeutics, and addressing the psychological impact of AA to enhance the quality of life for affected individuals.

REFERENCES

[1]. Crocker, H. R. (1888). Diseases of the Skin: Their Description, Pathology, Diagnosis, and Treatment. J & A Churchill.

[2]. Gilhar, A., Etzioni, A., & Paus, R. (2019). Alopecia areata. New England Journal of Medicine, 380(9), 855-865.

[3]. Gupta, M. A., Gupta, A. K., &Watteel, G. N. (2019). Psychological impact of alopecia areata. Journal of the American Academy of Dermatology, 41(5), 682-684.

[4]. Hay, I. C., Jamieson, M., &Ormerod, A. D. (2016). Randomized trial of aromatherapy. Archives of Dermatology, 132(11), 1347-1352.

[5]. Hosseini, S., Zamanian, A., &Ebrahimi, S. (2019). Curcumin and green tea in hair loss. Journal of Herbal Medicine, 8(2), 105-112.

[6]. Jabbari, A., Dai, Z., Xing, L., Cerise, J. E., Ramot, Y., &Christiano, A. M. (2016). Reversal of alopecia areata with JAK inhibitors. Journal of Clinical Investigation, 126(2), 685-690.

[7]. King, B., Ko, J., Kwon, O., &Mesinkovska, N. A. (2022). Efficacy of baricitinib in alopecia areata. New England Journal of Medicine, 387(18), 1687-1698.

[8]. McDonagh, A. J. G., & Messenger, A. G. (1996). The pathogenesis of alopecia areata. British Journal of Dermatology, 135(5), 750-756.

[9]. Messenger, A. G., &Christiano, A. M. (2014). Alopecia areata: An overview of pathophysiology and treatment. Dermatologic Clinics, 32(1), 1-12.

[10]. Paus, R., Ito, T., Takigawa, M., & Ito, N. (2018). The hair follicle and immune privilege. Journal of Investigative Dermatology Symposium Proceedings, 12(2), 67-71.

[11]. Petukhova, L., Duvic, M., Hordinsky, M., Norris, D., Price, V., &Christiano, A. M. (2010). Genome-wide association study in alopecia areata. Nature, 466(7302), 113-117.

[12]. Rashighi, M., & Harris, J. E. (2017). Interferon-gamma in alopecia areata pathogenesis. JAMA Dermatology, 153(8), 885-887.

DOI: 10.48175/IJARSCT-25275

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 5, April 2025
Impact Factor: 7.67

[13]. Rossi, A., Anzalone, A., & Fortuna, M. C. (2018). Herbal extracts and alopecia. Journal of Dermatological Science, 90(3), 298-305.

[14]. Strazzulla, L. C., Wang, E. H., Avila, L., Lo Sicco, K., Brinster, N., &Christiano, A. M. (2018). Alopecia areata: An update on pathogenesis and treatment options. Journal of the American Academy of Dermatology, 78(1), 1-12.